Value
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 3.0 |
| P/S | 9.9 |
| EV/EBITDA | 0.0 |
| Fwd P/E | 9.9 |
| PEG | 10.0 |
| Analyst target | 9.0 |
- ▸Forward P/E: 5.5x
- ▸PEG: 0.01
- ▸Attractively valued
TRUP · Why this verdict
Why Trupanion (TRUP) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.8/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Trupanion operates in pet insurance with a 41% analyst-implied upside and a 5.91x risk/reward ratio, but has missed earnings estimates in 3 of the last 4 quarters, burns significant cash at -53% of net income relative to free cash flow, and sits below its long-term moving averages — creating high-risk speculative exposure.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Free cash flow is -53% relative to net income — flagged as a red flag in earnings quality — combined with negative operating margin scores indicating that Trupanion's pet insurance model is currently consuming more cash than its income statement suggests, creating balance sheet pressure. Quality breakdown | Free cash flow as a percentage of net income improves above zero within four quarters, demonstrating that the business is beginning to generate positive operating cash flows to fund its growth rather than relying on financing activities. | →Stable |
| CounterInsurance companies build claims reserves that can temporarily distort free cash flow relative to reported earnings; the -53% ratio may reflect reserve building in a growing book of business rather than structural cash consumption. | ||
Analysts see 66% upside to a consensus target of $33.79 from the current price of $23.90, and the forward P/E of 5.5x with a PEG of 0.01 suggests that if Trupanion can achieve its growth targets, the stock would be meaningfully undervalued relative to those outcomes. Sentiment breakdown | Stock price appreciates at least 20% toward $28.00 within 12 months as enrollment growth in pet insurance drives revenue toward analyst target levels and earnings trajectory improves. | →Stable |
| CounterA 66% analyst upside combined with a stock trading near its 52-week low suggests that the analyst community has been consistently too optimistic; the market may be pricing in execution risk that analysts have not adequately discounted. | ||
Trupanion has missed earnings estimates in 3 of the last 4 quarters with an average negative surprise of -9.2%, including misses of -12%, -20%, and -14%, indicating that the company's cost structure or member acquisition economics are persistently more challenging than management or analyst models project. Earnings | At least 2 of the next 4 quarterly earnings reports deliver positive EPS surprise, demonstrating that execution is improving toward analyst projections as the membership base scales and claim loss ratios stabilize. | →Stable |
| CounterPet insurance is a high-growth market with significant investment in member acquisition; near-term earnings misses may reflect deliberate investment spending rather than structural underperformance of the core insurance economics. | ||
The stock is in a recovery pattern from a death cross with the 200-day moving average declining at -10.4% over 30 days — a steep confirmed downtrend — and sits at a technical score of zero out of 10, meaning there is no positive technical evidence to support near-term price appreciation. Momentum breakdown | The 200-day moving average slope reverses from its current -10.4% per 30 days to less than -3%, and the stock reclaims its 200-day moving average within six months, indicating the technical downtrend is resolving. | →Stable |
| CounterRSI at 71 with improving MACD and rising on-balance volume during a death cross recovery setup has historically been an early indicator of trend reversal; technical deterioration may be near its worst point. | ||
Free cash flow is -53% relative to net income — flagged as a red flag in earnings quality — combined with negative operating margin scores indicating that Trupanion's pet insurance model is currently consuming more cash than its income statement suggests, creating balance sheet pressure.
→StableQuality breakdown
- Expectation
- Free cash flow as a percentage of net income improves above zero within four quarters, demonstrating that the business is beginning to generate positive operating cash flows to fund its growth rather than relying on financing activities.
CounterInsurance companies build claims reserves that can temporarily distort free cash flow relative to reported earnings; the -53% ratio may reflect reserve building in a growing book of business rather than structural cash consumption.
Analysts see 66% upside to a consensus target of $33.79 from the current price of $23.90, and the forward P/E of 5.5x with a PEG of 0.01 suggests that if Trupanion can achieve its growth targets, the stock would be meaningfully undervalued relative to those outcomes.
→StableSentiment breakdown
- Expectation
- Stock price appreciates at least 20% toward $28.00 within 12 months as enrollment growth in pet insurance drives revenue toward analyst target levels and earnings trajectory improves.
CounterA 66% analyst upside combined with a stock trading near its 52-week low suggests that the analyst community has been consistently too optimistic; the market may be pricing in execution risk that analysts have not adequately discounted.
Trupanion has missed earnings estimates in 3 of the last 4 quarters with an average negative surprise of -9.2%, including misses of -12%, -20%, and -14%, indicating that the company's cost structure or member acquisition economics are persistently more challenging than management or analyst models project.
→StableEarnings
- Expectation
- At least 2 of the next 4 quarterly earnings reports deliver positive EPS surprise, demonstrating that execution is improving toward analyst projections as the membership base scales and claim loss ratios stabilize.
CounterPet insurance is a high-growth market with significant investment in member acquisition; near-term earnings misses may reflect deliberate investment spending rather than structural underperformance of the core insurance economics.
The stock is in a recovery pattern from a death cross with the 200-day moving average declining at -10.4% over 30 days — a steep confirmed downtrend — and sits at a technical score of zero out of 10, meaning there is no positive technical evidence to support near-term price appreciation.
→StableMomentum breakdown
- Expectation
- The 200-day moving average slope reverses from its current -10.4% per 30 days to less than -3%, and the stock reclaims its 200-day moving average within six months, indicating the technical downtrend is resolving.
CounterRSI at 71 with improving MACD and rising on-balance volume during a death cross recovery setup has historically been an early indicator of trend reversal; technical deterioration may be near its worst point.
Per-dimension breakdown
Quality
3.0/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 2.4 |
| ROA | 1.0 |
| Gross margin | 0.5 |
| Op margin | 0.5 |
| Net margin | 0.9 |
| Current ratio | 6.2 |
| FCF quality | 0.0 |
| Moat | 6.4 |
| Piotroski F | 8.9 |
- ▸Earnings quality RED FLAG: -53% FCF/NI
- ▸Strong Piotroski F-Score: 8/9
- ▸Quality concerns
Growth
5.6/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 5.6 |
Momentum
5.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 2.7 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 6.0 |
| Volume | 0.0 |
- ▸Overbought bear rally (RSI 75)
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope -10.3%/30d — confirmed downtrend
Sentiment
7.1/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 6.3 |
| Price target | 9.8 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (4.0) — signal dampened
- ▸Analyst upside: 64%
Insider
3.9/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 5.1 |
- ▸Modest insider selling — $395,522 (0.038% of mkt cap)
Peer rank
3.3/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 4.7 |
| quality rank | 0.9 |
| growth rank | 7.6 |
Technical
0.7/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.3 |
| support resistance | 0.8 |
| 52w position | 0.0 |
Risk (lower is worse)
4.4/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 4.6 |
| days to cover | 1.2 |
| volatility | 2.9 |
| put call | 6.7 |
| implied vol | 2.9 |
| max pain risk | 3.0 |
| beta | 5.3 |
| debt equity | 8.9 |
- ▸High IV: 63%
- ▸Above max pain $12
Catalyst
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
- ▸Earnings concerns: 1B/3M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (8)
- MOMENTUM:5.7>=5.5
- ASYMMETRY:3.0>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:46d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (1)
- DEATH_CROSS:momentum=5.7>=5.0 recovering
Reward-to-Risk
3.02
Upside
+39.0%
Downside
12.9%
Sizing output
AVOID
SetupRECOVERY — Death cross but MACD improving, RSI 75
EdgeNO_EDGE — No clear edge identified
SuitabilityAGGRESSIVE — Beta 1.43>1.3, MCap $1.0B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 7.5 could not lift the engine output above the verdict floor.
The strongest dimensions are Value at 7.5, Sentiment at 7.1, and Momentum at 5.7; the weakest are Technical at 0.7, Catalyst at 2.5, and Quality at 3.0. The V9 engine cleared all gates with 1 warning, producing an asymmetric reward-to-risk of 3.02 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Analysts see 66% upside to a consensus target of $33.79 from the current price of $23.90, and the forward P/E of 5.5x with a PEG of 0.01 suggests that if Trupanion can achieve its growth targets, the stock would be meaningfully undervalued relative to those outcomes.
Trip ifStock price falls below $20.00, more than 16% below the current $23.90, indicating the market has further discounted the analyst upside thesis beyond current levels.
- P2Trupanion has missed earnings estimates in 3 of the last 4 quarters with an average negative surprise of -9.2%, including misses of -12%, -20%, and -14%, indicating that the company's cost structure or member acquisition economics are persistently more challenging than management or analyst models project.
Trip ifEPS surprise falls below -15% in at least 3 of the next 4 quarters, indicating the miss pattern is deepening rather than stabilizing.
- P3Free cash flow is -53% relative to net income — flagged as a red flag in earnings quality — combined with negative operating margin scores indicating that Trupanion's pet insurance model is currently consuming more cash than its income statement suggests, creating balance sheet pressure.
Trip ifFree cash flow as a percentage of net income falls below -80% for 2 or more consecutive quarters, indicating accelerating cash burn that threatens balance sheet sustainability.
- P4The stock is in a recovery pattern from a death cross with the 200-day moving average declining at -10.4% over 30 days — a steep confirmed downtrend — and sits at a technical score of zero out of 10, meaning there is no positive technical evidence to support near-term price appreciation.
Trip ifThe 200-day moving average slope remains below -8% per 30 days for more than 4 consecutive months, indicating the steep downtrend is not resolving.